Logo

US BioDefense to Launch Open Source Platform for Stem Cell R&D

Jan 21, 2005

NEW YORK, Jan. 21 (GenomeWeb News) - US BioDefense is developing an open source stem cell research platform designed to enable researchers to use bioinformatics tools in order to read, distribute, modify, and contribute to research.

 

"We intend to quickly scale up revenues by focusing on selling open source collaborative technology research and transfer tools as well as commercializing leading edge technology," said US BioDefense CEO David Chin. He added that this will help the company tap into  California's $3 billion Stem Cell Research Fund."

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.